Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

LONDON and GAITHERSBURG, Md., April 21, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies and candidates, today announced that the Compensation Committee of the Company's Board of Directors granted stock option awards to purchase an aggregate of 68,500 American Depositary Shares and 57,765 restricted stock units (RSUs), each representing an equal number of ordinary shares, to 15 employees pursuant to the Company's 2025 Inducement Plan.